Medpace Holdings (NASDAQ: MEDP) CEO sells 7,238 shares at ~$600
Rhea-AI Filing Summary
August J. Troendle, President, CEO and 10% owner of Medpace Holdings, reported open-market sales of 7,238 common shares on July 27-28, 2026, executed under a limit order placed during an open window period. The trades comprised 3,728 shares at a weighted average price of $600.85 (range $600.00–$603.495) and 3,510 shares at a weighted average price of $600.01 (range $600.00–$600.45). A separate entry lists 4,733,019 common shares held indirectly by Medpace Investors, LLC, over which he has sole voting and investment control and may be deemed to indirectly beneficially own, while disclaiming beneficial ownership beyond his pecuniary interest. The filing states these transactions were not made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 7,238 shares
Net Sell
3 txns
Insider
Troendle August J.
Role
President & CEO
Sold
7,238 shs ($4.35M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F3 | 3,510 | $600.01 | $2.11M |
| Sale | Common Stock F1, F2 | 3,728 | $600.85 | $2.24M |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 638,946 shares (Direct);
Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)
Footnotes (4)
- F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
- F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.495. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $600.45. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Key Figures
Shares sold 2026-07-27: 3,728 shares
Shares sold 2026-07-28: 3,510 shares
Total shares sold: 7,238 shares
+3 more
6 metrics
Shares sold 2026-07-27
3,728 shares
Open-market sale of common stock at weighted average $600.85
Shares sold 2026-07-28
3,510 shares
Open-market sale of common stock at weighted average $600.01
Total shares sold
7,238 shares
Aggregate Medpace common shares sold on July 27-28, 2026
Indirectly held shares via Medpace Investors, LLC
4,733,019 shares
Common stock held by Medpace Investors, LLC; reporting person has sole voting and investment control
Weighted average price 2026-07-27
$600.85 per share
Weighted average sale price; individual trades ranged $600.00–$603.495
Weighted average price 2026-07-28
$600.01 per share
Weighted average sale price; individual trades ranged $600.00–$600.45
Key Terms
limit order, weighted average price, indirectly beneficially own, pecuniary interest, +1 more
5 terms
limit order financial
"transactions were effected pursuant to a limit order placed during an open window"
A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.
weighted average price financial
"The reported price is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirectly beneficially own regulatory
"may be deemed to indirectly beneficially own the securities of the Issuer held by MPI"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein"
open window period regulatory
"limit order placed by the Reporting Person during an open window period"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Medpace (MEDP) report for August J. Troendle?
Medpace reported that August J. Troendle sold 7,238 shares of common stock in open-market transactions on July 27-28, 2026. The sales were executed under a limit order during an open window period at weighted average prices around $600 per share.
Does August J. Troendle still have an indirect Medpace (MEDP) stake after these sales?
Yes. A separate holding entry shows 4,733,019 Medpace common shares held by Medpace Investors, LLC. Troendle has sole voting and investment control and may be deemed to indirectly beneficially own them, while disclaiming beneficial ownership beyond his pecuniary interest.
Were August J. Troendle’s Medpace (MEDP) stock sales under a Rule 10b5-1 trading plan?
The filing indicates the trades were not made under a Rule 10b5-1 trading plan. A footnote states they were effected pursuant to a limit order placed during an open window period, and the form’s 10b5-1 checkbox is left unchecked.
What is August J. Troendle’s role at Medpace (MEDP) in this Form 4?
In this Form 4, Troendle is identified as Medpace’s President, CEO and a 10% owner. The report covers his direct open-market stock sales and an indirect holding through Medpace Investors, LLC, where he has sole voting and investment control over the securities.